Find Clinical Trials

Inclusion Criteria: * Aged 18-60 years old; ② Right-handed; ③ Meet the DSM-5 diagnostic criteria for depression; ④ The current course of disease (last onset) is at least 2 weeks; ⑤HAMD-17 score ≥17 points; ⑥ No electroconvulsive therapy was received in the first six months. Exclusion Criteria: * A combination of another mental illness; A history of alcohol/drug dependence or smoking \> 10 cigarettes/day; ③ Serious physical diseases of the heart, liver, kidney, brain and hematopoietic system, central nervous system infection, head injury, epilepsy, multiple sclerosis, toxic metabolic diseases, Parkinson's disease or intracranial tumors; ④ Family history of hereditary diseases; ⑤Endocrine system diseases such as diabetes, hyperthyroidism or hypothyroidism; ⑥ Pregnant, lactating women or photosensitivities.

Inclusion Criteria: * Women * Age between 18 and 45 years (inclusive) * Mild to moderate depressive symptoms, defined by a score of 17 to 23 on the 17-item Hamilton Depression Rating Scale (HDRS-17) * Fluent in Spanish * Access to the internet and the ability to use digital devices (e.g., smartphone, tablet, or computer) Exclusion Criteria: * Currently receiving psychological therapy * Participation in any other interventional clinical trial for depression within the past 3 months * Pregnant or planning to become pregnant during the study period * Cognitive impairment that may interfere with informed consent or study participation * Presence of psychotic symptoms, active suicidal ideation, or current substance abuse disorder

Patients with T2D Inclusion Criteria: * Ages 30-75 * BMI (Body Mass Index) 21-45 kg/m2 * HbA1c = 7.0-11% * eGFR (estimated glomerular filtration rate)\> 60 ml/min/1.73m2 * Blood Pressure (BP)≤160/90 mmHg * Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH/T4 (thyroid/thyroxine hormone), EKG (electrocardiogram), and urinalysis (UA) * Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program * Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas/Metformin (Sulfo/MET) * Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment. * Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment. * SGLT2 inhibitors must be discontinued at least two months prior to study enrollment. * Statin therapy is permissible if the dose has been stable for at least 3 months EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: * Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded. * Patients taking medications other than Sulfonylureas/Metformin (SU/MET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \* * Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \< 60 are excluded * Women of childbearing potential are excluded unless they are taking/using appropriate contractive medications/devices \* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor. If their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%. HbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase. After two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.

Inclusion Criteria: * Age ≥18 years * Acute spontaneous Intracerberal Hemorrhage confirmed by imaging * Symptom onset to stroke center admission \<6 hours * Elevated systolic blood pressure (\>140 mmHg) at admission Exclusion Criteria: * Secondary causes of ICH (e.g., trauma, vascular malformation) * Presumed fatal bleeding at admission * Short remaining life expectancy (\<12 month)

Inclusion Criteria: 1. Age ≥18.0 years old at time of consent. 2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months. 3. Hemoglobin A1c (HbA1c) ≥ 7.0%. 4. Currently using an approved long-acting insulin for at least 3 months (e.g., insulin glargine, insulin degludec). 5. Treated or about to be treated with multi-drug therapies for T2D. 6. If using a CGM, willingness to wear an additional study CGM during the duration of the study. 7. Access to the internet and willingness to upload data during the study as needed. 8. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females who self-report that they are of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued. Exclusion Criteria: 1. Currently using rapid insulin for at least three months (e.g., insulin aspart, insulin lispro, insulin regular). 2. Currently being treated for a seizure disorder. 3. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol, such as but not limited to, the following examples: 1. Seizure disease 2. Decompensated cardiac disease 4. Inpatient psychiatric treatment in the past 6 months 5. Presence of a known adrenal disorder 6. Currently pregnant or intent to become pregnant during the trial. 7. Anticipated surgical, interventional procedures or prolonged periods of fasting during this study.

Inclusion Criteria: * ≥18 years of age at the time of signing informed consent. * Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC * Able to complete study questionnaires in English or Spanish * Breast cancer patients must have completed primary therapy (surgery, and/or chemotherapy, and/or radiation therapy) or currently on maintenance therapy * Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM) * Currently have no clinical evidence of disease * Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\]) * A total score of 4 or greater in VAS * Without history of other cancers (excluding non-melanoma skin cancer) * Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study Exclusion Criteria: * Inability to provide informed consent * Vaginal bleeding of unknown etiology within 12 months of study entry * Currently taking hormone replacement therapy \[local or systemic\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment) * Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment) * No known allergies to any ingredients in 10mg HLA suppository

Inclusion Criteria: 1. Adult (age 18 years or older) 2. Pregnant or postpartum and living with their infant 0-6 months old. This includes all individuals who identify as women, as well as those of female sex who do not identify as women (e.g., non-binary, trans) who are the primary parent for their infant. This includes via natural birth, adoption, or surrogacy. 3. EPDS score \>10 at eligibility screening. Exclusion Criteria: 1. Active alcohol or substance use disorder, mania or psychotic disorder (as these conditions are better managed in direct specialty care). 2. Active suicide plan or intent (as emergent hospital-based care is likely required), 3. Plan to move out of Ontario during the study. 4. Unable to complete relevant study procedures and measures online. For the few participants without access to devices/home internet, we will budget for tablets/data plans. 5. Unable to complete study activities in English. Note that Google translate is available for the intervention platform and language lines are available for participants so that they can be served in their language of choice, however we are unable to provide translations of all study assessment and questionnaire materials that participants will need to complete during the study. 6. No primary care clinician (required for collaborative mental health care delivery model). 7. Currently enrolled in a collaborative mental health care model.

Inclusion Criteria: * To be between 18-80 years old, * Volunteering to participate in the research, * At least 15 months after breast cancer surgery, * No problems in reading and/or understanding the scales and being able to co-operate with the tests. * Physically inactive (60 minutes of structured exercise per week \<). Exclusion Criteria: * Presence of active infection, * Presence of bilateral breast cancer, * History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery, * Having a neurological disease or other clinical diagnosis that may affect cognitive status, * Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease. * Presence of unstable hypertension or diabetes mellitus.

Patient Eligibility Inclusion Criteria: 1. ≥18 years old. 2. Pathologically confirmed diagnosis, with a focus on, but not limited to, colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancers. 3. Self-reported ability to read and speak English. 4. Able to provide informed consent. Patient Eligibility Exclusion Criteria: 1. ≤18 years old. 2. Does not have a pathologically confirmed diagnosis of cancer. 3. Currently receiving active cancer treatment (e.g., active chemotherapy, radiation therapy or stem cell transplant); patients on stable maintenance therapy are eligible (e.g., endocrine therapy, targeted therapy, or select immunotherapy). 3\) Does not live within the state of Florida. 3) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent. Provider Eligibility Inclusion Criteria 1. ≥18 years old. 2. Currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics. 3. Self-reported ability to read and speak English or Spanish. 4. Able to provide informed consent. Provider Eligibility Exclusion Criteria 1. ≤ 18 years old. 2. Does not currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics. 3. Does not self-report having the ability to read and speak English. 4. Not able to provide informed consent.

Inclusion Criteria: * adult 18-45 years of age * diagnosis of type 2 diabetes in the last 5 years, as evidenced in the electronic medical record * no prior use or experience with wearable CGMs * possession of a smart phone that is compatible with Dexcom CGM sensors (nearly all smartphones are compatible) and willing to download and utilize the Dexcom CGM app * fluency in English or Spanish Exclusion Criteria: * severe mental illness (e.g., psychosis, suicidal ideation); * pregnancy or \<6 months postpartum

Inclusion Criteria: 1. Adults (≥18 years old) with histologically or cytologically confirmed advanced or metastatic breast cancer 2. Received prior treatment with at least one of the following: CDK4/6 inhibitors, PIK3CA inhibitors, trastuzumab deruxtecan (T-DXd), or other targeted therapies 3. Documented disease progression following prior targeted therapy 4. Initiated a subsequent line of systemic therapy (chemotherapy, endocrine therapy, targeted therapy, or combination) after resistance 5. Available clinical data including baseline characteristics and treatment details 6. At least one follow-up evaluation after initiation of post-resistance therapy Exclusion Criteria: 1. Incomplete medical records or missing key clinical follow-up data 2. Concurrent diagnosis of other active malignancies (except non-melanoma skin cancer or in situ cervical cancer) 3. Known central nervous system disease requiring immediate local treatment (unless clinically stable) 4. Poor general condition with an Eastern Cooperative Oncology Group (ECOG) performance status ≥2 5. Life expectancy estimated to be less than 6 months based on clinical judgment

Inclusion Criteria: 1. Women aged 18 to 70 years old; 2. In the first diagnosis of unilateral breast cancer patients, the maximum diameter of invasive tumor is ≤ 5cm, and there is no requirement for tumor size of carcinoma in situ in principle; 3. Patients undergoing preventive mastectomy are not allowed to be included in the study; 4. Clinical examination and auxiliary examinations suggest that the tumor is confined to the mammary gland and has not invaded the nipple areola complex, skin, or chest wall; 5. Clinical axillary lymph node negative (clinical physical examination and imaging suggest negative axillary lymph nodes; for suspected positive axillary lymph nodes, fine needle aspiration or hollow needle biopsy is required to confirm negative); 6. Sentinel lymph node biopsy negative; 7. Patients with low load positive axillary lymph nodes (isolated tumor cells, micro or macro metastases), but exempted from adjuvant radiotherapy after surgery; 8. Patients who are not suitable for breast conserving surgery or who are unwilling to undergo breast conserving surgery and plan to undergo laparoscopic assisted mastectomy with preservation of the nipple and areola, as well as immediate one-step breast reconstruction with a breast prosthesis combined with a chest muscle prosthesis and simultaneous fat transplantation; If frozen pathology or routine pathology indicates a positive posterior margin of the nipple, it is allowed to remove the nipple, but the areola must be preserved; 9. The volume of the prosthesis is less than 500cc; 10. During the observation period of the study, the affected side may consider re fat injection, but symmetrical surgery is not allowed on the healthy side; 11. ECOG score 0-1 points; 12. New adjuvant chemotherapy patients are allowed to be enrolled; 13. No smoking history or quitting smoking for at least 4 weeks; 14. The researcher determines that they are able to comply with the research protocol; 15. Those who participate in other clinical trials (including intervention or non intervention studies) at the same time and are judged by the researchers to not affect the study protocol can be enrolled normally; 16. After obtaining sufficient information, voluntarily participate and sign an informed consent form. Exclusion Criteria: 1. Specialized physical examination and/or auxiliary examination suggest that the tumor involves the nipple areola complex (including Paget's disease) or the skin; 2. Double breast cancer; 3. Bilateral breast reconstruction patients; 4. Patients who have undergone fat injection, breast augmentation with implants, and breast reduction surgery in the past; 5. Patients with incomplete immune function, poor control of diabetes and active smoking; 6. Patients with severe breast sagging; 7. Breast cup size ≥ E; 8. Accept two-step breast reconstruction using dilators/prostheses, autologous breast reconstruction, and breast reconstruction performed through open surgery; 9. Patients who have previously received and/or received postoperative radiotherapy for the reconstruction site or chest wall; 10. Patients who plan to undergo symmetrical surgery on the healthy breast during the visit period; 11. Patients with mental illnesses or abnormalities who are expected to be unable to independently complete the BREAST-Q scale; 12. Pregnant and lactating patients; 13. Poor compliance, unable to conduct relevant examinations and follow ups according to the trial requirements; 14. Suffering from serious accompanying diseases or other comorbidities that may interfere with planned treatment, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study.

Inclusion criteria: 1. Subject with age ≥18 years or minimum age as required by local regulations and ≤ 70 years old at time of consent 2. Subject with hypertension who has an office BP of ≥ 150/90 mmHg and \< 180/110 mmHg (meet both SBP and DBP criteria) at Screening V2, and mean daytime ASBP ≥ 140 mmHg and \< 170 mmHg by 24-hour ABPM at Screening V2. 3. Willing and able to provide informed consent 4. Willing and able to comply with all study-specific visits, assessments, and requirements Exclusion Criteria: 1. 1\. Subject who is pregnant, nursing or planning to become pregnant during the course of the study 2. Subject with unilateral or bilateral renal artery that are not suitable for ablation procedure (renal artery stenosis more than 50%, renal aneurysm, renal artery abnormality, renal artery diameter \< 3 mm or treatable segment length \< 20 mm) 3. Subject with single-kidney or history of kidney transplant 4. Subject with history of renal artery intervention (Percutaneous Transluminal Angioplasty \[PTA\] or stenting) or Renal Denervation (RDN) 5. Subject with any conditions that may affect the accuracy of blood pressure (BP) measurement: such as the diameter of the upper arm is too large for the cuff, or arrhythmia, etc 6. Subject with known secondary hypertension 7. Subject with eGFR \<40 mL/min/l.73m² 8. Subject with history of hospitalization for hypertensive emergency within past year 9. Subject with type I diabetes mellitus 10. Subject with primary pulmonary hypertension 11. Subject with history of bleeding diathesis and haematological disorders or coagulopathy 12. Subject with recent history of any embolism within 6 months 13. Subject with history of coronary artery intervention, unstable angina or myocardial infarction 14. Subject with stable angina and therefore treated anti-anginal medication (betablockers, calcium antagonists, long-acting nitrates) 15. Subject with history of abdominal aortic aneurysm 16. Subject with atrial fibrillation or history of atrial fibrillation in the last 3 years or on rate or rhythm control medication for arrhythmia 17. Subject with a history of ventricular fibrillation or ventricular tachycardia 18. Subject known with serum Human Immunodeficiency Virus (HIV)-positive 19. Subject who is allergic to contrast agents and not responding to preventive medication 20. Subject with acute or severe systemic infections 21. Subject with mental illness or any psychological problems that may interfere with participating in the study 22. Subject with history of stroke or transient ischemic attack (TIA) 23. Subject with malignant tumors or end-stage disease 24. Subject with severe Peripheral Artery Disease (PAD) along the access path to renal arteries, including abdominal aneurysm 25. Subject with severe heart valve stenosis or regurgitation 26. Subject with heart failure requiring medications (i.e. Angiotensin-Converting Enzyme (ACE)/ Angiotensin II Receptor Blockers (ARB), Sodium-Glucose Cotransporter 2 Inhibitors (SGTL2i), diuretics) 27. Subject with uncontrolled hyperthyroidism or hypothyroidism 28. Subject with severe electrolyte abnormalities, defined as values above and below the limits of normal (LN) on repeated measurements despite normalization efforts, or with liver function abnormalities, defined as 2 \> Upper Limit of Normal (ULN) 29. Subject who requires mechanical ventilation other than Continuous Positive Airway Pressure (CPAP) for sleep apnea 30. Subject with an implanted pacemaker or Implantable Cardioverter Defibrillator (ICD)/ Cardiac Resynchronization Therapy (CRT) device 31. Subject with a history of major surgery or trauma within 30 days prior to enrolment 32. Subject who has planned surgery or cardiovascular intervention within the next 12 months 33. Subject who is participating in other drug or medical device clinical investigations 34. Subject who is unsuitable to participate in this study in the opinion of investigators (e.g., drug use or alcohol dependency, cognitive impairment, etc.)

Inclusion Criteria: * Women who are breast cancer survivors and clinically confirmed to be disease-free by their physician. * Amenorrhea for more than 12 months and vaginal pH ≥ 5, with symptoms related to genitourinary syndrome of menopause (GSM), as diagnosed by a physician. Symptoms must be bothersome and not better explained by another clinical condition. * Negative urine culture at baseline. * Moderate to severe vaginal dryness, defined as a score \> 4 on the Numeric Rating Scale (NRS 0-10) Exclusion Criteria: * Age over 75 years. * Current or past diagnosis of any cancer other than breast cancer. * Pelvic surgery, chemotherapy, or radiotherapy in the past 3 months. * Use of local estrogen therapy within the past month. * Active genital infections. * Diagnosis of HIV infection or severe immunosuppression. * Presence of pacemakers, metallic implants, or electromagnetic devices. * Coagulation disorders or current use of anticoagulants. * Pelvic organ prolapse stage \> III (POP-Q classification). * Unexplained abnormal vaginal bleeding. * History of pelvic anti-incontinence surgery, with or without mesh. * Inflammatory dermatoses of the vulva. * Pelvic-floor muscle strength score of 0/5 on the Modified Oxford Scale. * Nickel allergy. * Previous treatment with radiofrequency in the pelvic or genital area.

Inclusion Criteria: * Able to understand and comply with procedures of the protocol, and voluntarily sign the Informed Consent Form. * Age ≥ 18 years old and ≤ 75 years old. * Body mass index (BMI) ≥ 18.0 kg/(m\*m). * Documented treatment with medium to high dose Inhaled Corticosteroids (ICS) in combination with asthma controller medication for at least 3 months with a stable dose ≥1 month prior to Visit 1. * Documented history of at least 1 severe asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS. * Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5 Exclusion Criteria: * Women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating. * With a history of drug abuse within the past 5 years before screening visit. * Allergic or intolerant to CM512 injection or placebo components, or with a history of severe drug allergies or anaphylactic shock. * With any medical or non-medical conditions that are not suitable for participation in this study by investigators.

Inclusion Criteria: Participants will be drawn from the broader PRIL (Perinatal mental health Profiling and Intervention in Leuven) study, who consented to being contacted for the intervention trial and who meet criteria for moderate risk for perinatal depression based on an analytical epidemiological approach aligned with precision medicine principles, specifically a concentration-of-risk prediction modeling approach. Based on a comprehensive assessment of biological, psychological and social risk and protective factors, concentration-of-risk models will be developed and validated to stratify respondents in terms of risk for future perinatal depression, namely (1) not, (2) mildly, (3) moderately and (4) highly at risk of developing perinatal depression. Mothers falling into the moderate risk profile are eligible to participate Exclusion Criteria: * Receiving concurrent psychological guidance in perinatal mental health problems; * Not consenting to (a) audiorecording of the first two face-to-face sessions and/or (b) paying the appropriate fee, in case of randomization to the face-to-face intervention arm.

Inclusion Criteria: * Diagnosis of MODY via genetic testing * HgbA1c \>6.5% Exclusion Criteria: * History of anaphylaxis to GLP-1 receptor agonists * Already taking GLP-1 receptor agonists * on medications within the stimulant class * have had bariatric surgery * personal or family history of cancer, especially medullary thyroid cancer * personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis * known active kidney disease * severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment * HbA1c \> 10.0% * episode of diabetic ketoacidosis (DKA) in the past 3 months * are currently pregnant * BMI \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile

Inclusion Criteria: * Between 8 and 17 years of age * Individuals must have parental/guardian consent * Elevated levels of anxiety or depression based on 1. Screen for Child Anxiety Related Disorders (SCARED) score of 15 or higher, or; 2. Revised Children's Anxiety and Depression Scale (RCADS) Depression T score of 65 or higher, or; 3. Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) clinician severity rating of 3 on any anxiety disorder or on a mood-related disorder Exclusion Criteria: * Diagnosed with Conduct Disorder or with behavioral symptoms that would make it difficult for the child/adolescent to participate in the group or comply with directions given by the group leader (such as difficulty following instructions, difficulty staying in one's seat, defiance of adults, harming animals or people, threatening others, getting into physical fights, hyperactivity, impulsivity, difficulty waiting for one's turn, etc.) * Autism or developmental delays * Psychotic symptoms or active suicidality * Active Eating Disorders that raise concerns about morbidity and therefore need to be addressed in an intervention and actively monitored * Unsteady dosage or recently or impending changes to psychotropic medication(s) * Non-English-speaking individuals * Wards of the State

Inclusion Criteria: * Patients suffering from stage IV breast cancer * Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors) * Candidates for radiation treatment (both palliative and curative). Exclusion Criteria: * Previous radiation treatment on the same site * Absolute contraindications to radiotherapy * Systemic treatment administered as part of a clinical trial

Group 1 Inclusion Criteria * Age \> 18 years * Diagnosis of open-angle glaucoma (primary open-angle glaucoma) * Uncontrolled IOP (\> 21 mmHg as the mean of three measurements between 8-10 am and 16), * Maximal medical therapy * Perimetric-OCT and ophthalmic optic neuropathy criteria * Indication for standalone or combined glaucoma surgery (any surgery allowing aqueous humor sampling: MIGS, MIBS, TRABE, DS, canal surgery, drainage tube implants, revision of surgical implant) Group 2 and 4 Inclusion Criteria * Age \> 18 years * Diagnosis of open-angle glaucoma * Controlled IOP (≤ 21 mmHg as the mean of three measurements between 8-10 am and 16) under medical therapy (excluding oral acetazolamide) * Perimetric-OCT and ophthalmic optic neuropathy criteria. Group 3 Inclusion Criteria: * Age \>18 years * IOP ≤ 21 mmHg * Absence of perimetric-OCT and ophthalmic optic neuropathy criteria for glaucoma. Exclusion Criteria for all groups * Conditions and systemic therapies influencing NAM levels in biological fluids * Concomitant ocular pathologies beyond glaucoma or cataracts * Ocular therapies beyond hypotensive eye drops * Prior ocular surgeries * Secondary glaucomas (uveitic, silicone oil, traumatic, neovascular) * End-stage glaucoma or severe glaucoma (\<-20 dB) * Pregnancy and breastfeeding. * (only for Group 3) family history of glaucoma and transient IOP spikes